1. Scrip
  3. >>Clinical Trials

Celgene's CAR-T Leadership Goals Advance At ASH 2017

 
• By Mandy Jackson

Celgene's partnership strategy paid off at ASH with positive results for two CAR-T therapies in development with bluebird bio and Juno. The company is pursuing first- and best-in-class opportunities with the goal of becoming a leader in the CAR-T field.

T-cells attacking cancer_1200x675

Celgene Corp. hit a double whammy at the American Society of Hematology (ASH) meeting running Dec. 9-12 in Atlanta, Ga. via partners bluebird bio Inc. and Juno Therapeutics Inc. that could help the company meet its goal of becoming a leader in chimeric antigen receptor T cell (CAR-T) therapies.

Bluebird and Celgene reported new data for bb2121 showing strong, durable response rates in relapsed and refractory multiple myeloma as the Phase I clinical trial for their CAR-T therapy targeting B cell maturation antigen (BCMA) progresses

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.